PEM vs Liquid Biopsy for Breast Cancer
Trial Summary
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Liquid Biopsy for breast cancer?
Research shows that liquid biopsy, which involves analyzing circulating tumor cells (CTCs) in the blood, can help monitor breast cancer progression and treatment response. It is a non-invasive method that can detect cancer cells earlier and in smaller numbers compared to traditional tissue biopsies, making it a valuable tool for ongoing cancer management.12345
Is liquid biopsy safe for breast cancer patients?
How is the treatment 'Liquid Biopsy and PEM' different from other breast cancer treatments?
Liquid biopsy is a unique and non-invasive method that detects cancer cells in the blood, allowing for real-time monitoring of breast cancer without the need for painful tissue biopsies. It can identify circulating tumor cells and DNA, providing a comprehensive view of the disease's progression and potentially detecting cancer earlier than traditional methods.123410
What is the purpose of this trial?
The goal of this research study is to evaluate the performance of two experimental tests, namely Liquid Biopsy and Positron Emission Mammography (PEM) in women at high risk of breast cancer. The plan for this study is to assess whether findings from the combination or each individual test can assist radiologists in visualizing and characterizing beast abnormalities.Liquid Biopsy is a blood test that can detect early tumours in patients with malignancies, while PEM is an imaging tool equipped with a high-resolution camera that uses a low dose of injected positron emitting isotope to locate breast tumours. Participation in this study entails a blood draw for Liquid Biopsy test and a PEM imaging exam before undergoing a magnetic resonance imaging (MRI) - guided biopsy for a suspicious breast lesion.If PEM and/or Liquid Biopsy provide accurate information to assist radiologists in visualizing and characterizing breast abnormalities, this method may serve as the first step towards establishing these genomic and new imaging technologies as new diagnostic modalities and ultimately reduce the unnecessary biopsies and anxiety in high-risk populations.
Research Team
Vivianne Freitas, MD
Principal Investigator
University Health Network, Toronto
Eligibility Criteria
This trial is for women at high risk of breast cancer who are due to have an MRI-guided biopsy for a suspicious breast lesion. Participants will undergo two experimental tests: a blood test called Liquid Biopsy and an imaging exam known as Positron Emission Mammography (PEM).Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo a blood draw for Liquid Biopsy and a PEM imaging exam before an MRI-guided biopsy
Follow-up
Follow-up blood and tissue samples may be requested post-surgery if malignancy is confirmed
Outcome Evaluation
Evaluation of the performance of PEM and Liquid Biopsy in visualizing and characterizing breast abnormalities
Treatment Details
Interventions
- Liquid Biopsy
- Positron Emission Mammography (PEM)
Liquid Biopsy is already approved in United States, European Union, Canada for the following indications:
- Monitoring and diagnosis of various cancers including breast cancer
- Non-invasive diagnosis and monitoring of cancer, including breast cancer
- Diagnosis and monitoring of cancer, including breast cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor
Radialis Inc.
Industry Sponsor
The Princess Margaret Cancer Foundation
Collaborator